ArticleCancer research2010
Pituitary tumor transforming gene binding factor: a new gene in breast cancer.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer.Endocrine-related cancer · 2025Article
- Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes.Frontiers in immunology · 2023Article
- PTTG1IP (PBF) is a prognostic marker and correlates with immune infiltrate in ovarian cancer.American journal of translational research · 2023Article
- RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor.Frontiers in genetics · 2021Article
- Hypermethylation of theOncology letters · 2019Article
- The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy.Scientific reports · 2019Article
- The long non-coding RNA PTTG3P promotes growth and metastasis of cervical cancer through PTTG1.Aging · 2019Article
- Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study.Frontiers in endocrinology · 2019Article
- PTTG and PBF Functionally Interact with p53 and Predict Overall Survival in Head and Neck Cancer.Cancer research · 2018Article
- Article
- Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.Oncogene · 2017Article
- Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF.Endocrine-related cancer · 2017Article
- Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin.The Journal of clinical endocrinology and metabolism · 2016Article
- Prognostic implications of securin expression and sub-cellular localization in human breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.Endocrinology · 2014Article
- MicroRNA-584 functions as a tumor suppressor and targets PTTG1IP in glioma.International journal of clinical and experimental pathology · 2014Article
- Cancer: Novel target to enhance radioiodine uptake in thyroid cancer.Nature reviews. Endocrinology · 2013Article
- Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.The Journal of clinical endocrinology and metabolism · 2013Article
- Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Pituitary tumor transforming gene (PTTG) binding factor (PBF; PTTG1IP) is a relatively uncharacterized oncoprotein whose function remains obscure. Because of the presence of putative estrogen response elements (ERE) in its promoter, we assessed PBF regulation by estrogen. PBF mRNA and protein expression were induced by both diethylstilbestrol and 17beta-estradiol in estrogen receptor alpha (ERalpha)-positive MCF-7 cells. Detailed analysis of the PBF promoter showed that the region -399 to -291 relative to the translational start site contains variable repeats of an 18-bp sequence housing a putative ERE half-site (gcccctcGGTCAcgcctc). Sequencing the PBF promoter from 122 normal subjects revealed that subjects may be homozygous or heterozygous for between 1 and 6 repeats of the ERE. Chromatin immunoprecipitation and oligonucleotide pull-down assays revealed ERalpha binding to the PBF promoter. PBF expression was low or absent in normal breast tissue but was highly expressed in breast cancers. Subjects with greater numbers of ERE repeats showed higher PBF mRNA expression, and PBF protein expression positively correlated with ERalpha status. Cell invasion assays revealed that PBF induces invasion through Matrigel, an action that could be abrogated both by siRNA treatment and specific mutation. Furthermore, PBF is a secreted protein, and loss of secretion prevents PBF inducing cell invasion. Given that PBF is a potent transforming gene, we propose that estrogen treatment in postmenopausal women may upregulate PBF expression, leading to PBF secretion and increased cell invasion. Furthermore, the number of ERE half-sites in the PBF promoter may significantly alter the response to estrogen treatment in individual subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.